Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment

T.W. Kouwenberg, B.J.C. van den Bosch, J. Bierau, D.M.W.M. te Loo, M.J.H. Coenen, M.M. Hagleitner

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E94-E97
Number of pages4
JournalJournal of Pediatric Hematology Oncology
Volume42
Issue number2
DOIs
Publication statusPublished - 1 Mar 2020

Keywords

  • 6-mercaptopurine
  • acute lymphoblastic leukemia
  • azathioprine
  • children
  • disease
  • itpa
  • pharmacogenetics
  • polymorphisms
  • population
  • susceptibility
  • therapy
  • thiopurine methyltransferase activity
  • tpmt
  • POPULATION
  • TPMT
  • SUSCEPTIBILITY
  • AZATHIOPRINE
  • THIOPURINE METHYLTRANSFERASE ACTIVITY
  • CHILDREN
  • POLYMORPHISMS
  • THERAPY
  • DISEASE
  • PHARMACOGENETICS
  • ITPA

Cite this